Index for CREATE


CREATE Act


[return to index]


Revenue Issuances

Revenue Regulations

No. of Issuance Subject Matter Date of Issue
 RR No. 2-2021  Amends certain provisions of RR No. 2-98, as amended, to implement the amendments introduced by RA No. 11534 (Corporate Recovery and Tax Incentives for Enterprises Act or CREATE Act) to the NIRC of 1997, as amended, relative to the Final Tax on certain passive income
(Published in Philippine Star and  Malaya Business Insight on April 9, 2021)
Digest | Full Text
 April 8, 2021
RR No. 3-2021 Prescribes the Rules and Regulations to implement Section 3 of RA No. 11534 (Corporate Recovery and Tax Incentives for Enterprises Act or CREATE Act), amending Section 20 of the NIRC of 1997
(Published in Philippine Star on April 9, 2021)
Digest | Full Text 
April 8, 2021
RR  No. 4-2021 Implements the provisions on Value-Added Tax (VAT) and Percentage Tax under RA No. 11534 (Corporate Recovery and Tax Incentives for Enterprises Act or CREATE Act), which further amended the NIRC of 1997, as amended, as implemented by RR No. 16-2005, as amended
(Published in Philippine Star on April 9, 2021)
Digest | Full Text 
April 8, 2021
RR No. 5-2021 Implements the new Income Tax rates on the regular income of corporations, on certain passive incomes, including additional allowable deductions from Gross Income of persons engaged in business or practice of profession pursuant to RA No. 11534 (Corporate Recovery and Tax Incentives for Enterprises Act or CREATE Act), which further amended the NIRC of 1997
(Published in Philippine Star and Malaya Business Insight on April 9, 2021)
Digest | Full Text 
April 8, 2021
RR No. 8-2021 Amends certain provisions of RR No. 4-2021, which implemented the VAT and Percentage Tax provisions under RA No. 11534 (CREATE Act)
(Published in Philippine Star on June 12, 2021)
Digest | Full Text
June 11, 2021
RR No. 21-2021 Amends certain provisions of RR No. 16-2005, as amended by RR Nos. 4-2007, 13-2018, 26-2018 and 9-2021 to implement Sections 294 (E) and 295 (D), Title XIII of the NIRC of 1997, as amended by RA No. 11534 (CREATE Act), and Section 5, Rule 2 and Section 5, Rule 18 of the CREATE Act Implementing Rules and Regulations
(Published in Manila Times on December 10, 2021)
Digest | Full Text
December 7, 2021
RR No. 4-2022 Implements Section 295(F), in relation to Section 294, both of the NIRC of 1997, as amended by RA No. 11534 (CREATE Act), on the tax treatment of the importation of petroleum and petroleum products into, and subsequent transfer, transport and/or withdrawal through and from Freeport Zones and Economic Zones
(Published in Manila Times on May 30, 2022)
Digest |Full Text
May 26, 2022
RR No. 3-2023 Amends certain provisions of RR No. 16-2005, as amended by RR No. 21-2021, to implement Sections 294 (E) and 295 (D), Title Xlll of the NIRC of 1997, as amended by RA No. 11534 (CREATE Act), and Section 5, Rule 2 and Section 5, Rule 18 of the CREATE Act IRR, as amended
(Published in Manila Times on April 28, 2023)
Digest | Full Text
April 27, 2023


Revenue Memorandum Circulars

No. of Issuance
Subject Matter
Date of Issue
RMC No. 62-2021 Clarifies certain provisions of Revenue Regulations No. 5-2021 relative to Corporate Income Taxation
Digest | Full Text
May 17, 2021
RMC No. 67-2021 Clarifies the issues relative to the temporary reduction of Percentage Tax rate imposed under Section 116 of the NIRC of 1997, as amended by Section 13 of RA No. 11534 (CREATE Act)
Digest Full Text
May 24, 2021
RMC No. 76-2021 Clarifies the illustrative examples in the computation of Corporate Income Tax under Section 3(B) and 3(D) of Revenue Regulations No. 5-2021
Digest | Full Text
June 15, 2021
RMC No. 81-2021 Publishes the letter from the Food and Drug Administration containing the “List of VAT-Exempt Products” pursuant to RA No. 11534 (CREATE Act)
Digest | Full Text | FDA Endorsement Letter | List of VAT-Exempt Products
July 6, 2021
RMC No. 83-2021 Circularizes the Implementing Rules and Regulations of Title XIII of RA No. 8424 otherwise known as the "National Internal Revenue Code of 1997", as amended by RA No. 11534 (CREATE Act)
Digest |  Full Text | IRR
July 12, 2021
RMC No. 89-2021 Circularizes RA No. 11534, titled “An Act Reforming the Corporate Income Tax and Incentives System, Amending for the Purpose Sections 20, 22, 25, 27, 28, 29, 34, 40, 57, 109, 116, 204 and 290 of the National Internal Revenue Code of 1997, as Amended, and Creating Therein New Title XIII, and for Other Purposes”, otherwise known as “Corporate Recovery and Tax Incentives for Enterprises Act” or CREATE”
Digest | Full Text | RA No. 11534 | Veto
July 19, 2021
RMC No. 99-2021 Clarifies issues relative to the Value-Added Tax (VAT) Exemption of certain medicines and other medicinal devices for COVID-19 under Sections 109(1)(AA) and 109(1)(BB)(ii) of the National Internal Revenue Code of 1997 (Tax Code), as amended by Republic Act (RA) Nos. 10963 (TRAIN Law), 11467 and 11534 (CREATE Act)
Digest | Full Text
September 1, 2021
RMC No. 103-2021 Publishes the full text of the letters from the Food and Drug Administration and the Department of Health containing updates to the List of VAT-Exempt Products under Republic Act (RA) Nos. 10963, 11467 and 11534
Digest | Full Text | Updates to the List of VAT-Exempt Products | Endorsement of the List of VAT-Exempt COVID-19 Medicines | List of VAT-Exempt COVID-19 Medicines
October 1, 2021
RMC No. 115-2022 Publishes the full text of the letters from the Department of Health containing updates to the list of VAT-exempt COVID-19 products under RA No. 11534
Digest | Full Text | Attachment 1 | Attachment 2
November 19, 2021
RMC No. 120-2021 Circularizes the Amendments to Rule 2, Sections 4, 5 and 8; Rule 3 Section 3; Rule 17 Section 2, and Rule 18 Section 5, and Addition of a New Rule 18 Section 6 of the Implementing Rules and Regulations of Title XIII of RA No. 8424 (National Internal Revenue Code of 1997), as amended by RA No. 11543 (CREATE Act)
Digest | Full Text | Annex A
December 13, 2021
RMC No. 123-2021 Publishes the full text of letter from the Department of Health endorsing updates to the List of VAT-Exempt COVID-19 Medicines under Republic Act No. 11534
Digest | Full Text | Attachment
December 14, 2021
RMC No. 124-2021 Publishes the full text of letter from the Food and Drug Administration endorsing updates to the List of VAT-Exempt COVID-19 Medicines under Republic Act No. 11534
Digest | Full Text | Annex A | List of VAT-Exempt Products Under RA No. 11534
December 14, 2021
RMC No. 2-2022
Publishes the full text of letter from the DOH endorsing updates to the List of VAT-Exempt COVID-19 Medicines under RA No. 11534
January 10, 2022
RMC No. 5-2022
Publishes the letter from the Food and Drug Administration endorsing updates to the List of VAT-Exempt Products under RA Nos. 10963 and 11534
January 17, 2022
RMC No. 17-2022 Publishes the full text of letter from the DOH endorsing updates to the List of VAT-Exempt COVID-19 Medicines under RA No. 11534
Digest | Full Text
January 31, 2022
RMC No. 19-2022 Provides clarification and guidance on Section 8 of RR No. 5-2021 on the tax-free exchanges of properties under Section 40(C)(2) of the NIRC of 1997, as amended by RA No. 11534 (CREATE)
Digest | Full Text | Annex A | Annex A-1 | Annex A-2 | Annex B
February 4, 2022
RMC No. 24-2022 Clarifies issues relative to RR No. 21-2021 implementing the amendments to the Value-Added Tax (VAT) zero rating provisions under Sections 106 and 108 of the National Internal Revenue Code of 1997 (Tax Code), in relation to Sections 294(E) and 295(D), Title XIII of the Tax Code, introduced by RA No. 11534 (CREATE Act), and Section 5, Rule 2 and Section 5, Rule 18 of the CREATE Act Implementing Rules and Regulations
Digest | Full Text
March 9, 2022
RMC No. 28-2022 Prescribes the guidelines in the submission of the Certificate of Entitlement to Tax Incentives (CETI) under Republic Act No. 11534 (Corporate Recovery and Tax Incentives for Enterprises (CREATE) Law)
Digest Full Text
March 16, 2022
RMC No. 30-2022 Publishes the full text of the letter from the Food and Drug Administration of the Department of Health (DOH) endorsing updates to the List of VAT-Exempt Medicines under Republic Act No. 11534 (CREATE) Act
Digest Full Text | Annex A
March 16, 2022
RMC No. 47-2022 Publishes the full text of the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
Digest | Full Text
April 19, 2022
RMC No. 49-2022 Amends pertinent portion of the Questions and Answers in RMC No. 24-2022 to align them with the provisions of CREATE Act and its Implementing Rules and Regulations
Digest | Full Text 
April 20, 2022
RMC No. 51-2022 Publishes the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
Digest | Full Text | Annex A
April 21, 2022
RMC No. 56-2022 Publishes the full text of the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt medicines under RA No. 11534 (CREATE Act)
Digest | Full Text | Annex A
April 27, 2022
RMC No. 57-2022 Publishes the full text of the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt medicines under RA No. 11534 (CREATE Act)
Digest | Full Text | Annex A
April 27, 2022
RMC No. 58-2022 Publishes the full text of the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt medicines under RA No. 11534 (CREATE Act)
Digest | Full Text | Annex A
April 27, 2022
RMC No. 59-2022 Publishes the full text of the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt medicines under RA No. 11534 (CREATE Act)
Digest | Full Text | Annex A
April 27, 2022
RMC No. 66-2022
Publishes the full text of the April 8, 2022 letter from the Food and Drug Administration of the DOH endorsing updates to the List of Medical Devices Exempt from VAT under RA No. 11534 (CREATE Act)
May 2, 2022
RMC No. 68-2022
Publishes the full text of the April 26, 2022 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt medicines under RA No. 11534 (CREATE Act)
May 12, 2022
RMC No. 83-2022
Publishes the May 18, 2022 letter from the Food and Drug Administration (FDA) of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
June 30, 2022
RMC No. 110-2022
Publishes the May 30, 2022 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
July 21, 2022
RMC No. 112-2022
Publishes the June 27, 2022 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
July 28, 2022
RMC No. 113-2022
Publishes the July 1, 2022 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
July 28, 2022
RMC No. 116-2022
Publishes the July 11, 2022 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
August 4, 2022
RMC No. 119-2022
Publishes the July 20, 2022 letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)
August 8, 2022
RMC No. 69-2023 Reverts the rates of Percentage Tax, Minimum Corporate Income Tax, and Regular Corporate Income Tax on proprietary educational institutions and not for profit hospitals, pursuant to RA No. 11534 (CREATE Act)
Digest | Full Text 
June 20, 2023

 

Revenue Memorandum Orders

No. of Issuance
Subject Matter
Date of Issue
     

[return to index]


Forms

Form No.
Form Title
   

[return to index]


Advisories

  •  Advisory for mandated users of eBIRForms regarding payment of the Final Income Taxes Withheld. more

[return to index]


Announcements

 


[return to index]


News Articles


[return to index]